Risk stratifying the acute coronary syndrome patient: a focus on treatable risk
1Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA.
Insights
Diagnosing acute coronary syndrome (ACS) is challenging. Troponin testing is crucial for identifying high-risk patients and guiding treatment, especially differentiating between unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI).
Area of Science:
- Cardiology
- Emergency Medicine
- Diagnostic Testing
Background:
- Chest pain presentation in emergency rooms often poses diagnostic challenges for acute coronary syndrome (ACS).
- Current guidelines, like those from the American College of Cardiology (ACC)/American Heart Association (AHA), group unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) together.
- Distinguishing between general risk and treatable risk is a key clinical dilemma.
Purpose of the Study:
- To highlight the importance of troponin level evaluation in suspected ACS cases.
- To emphasize the role of troponin testing in optimizing treatment decisions and patient outcomes.
- To differentiate the management of troponin-positive versus troponin-negative patients.
Main Methods:
- Review of existing data and clinical guidelines concerning ACS diagnosis and treatment.
- Analysis of the impact of troponin levels on risk stratification and intervention efficacy.
- Comparison of treatment benefits in troponin-negative versus troponin-positive patient cohorts.
Main Results:
- Troponin level evaluation aids in identifying high-risk ACS patients, guiding early decision-making.
- In troponin-negative patients, routine interventions (e.g., unfractionated heparin, glycoprotein IIb/IIIa inhibitors, invasive procedures) show no benefit in reducing death or myocardial infarction (MI).
- Troponin status is essential for optimizing patient outcomes and safety, despite combined guideline classifications.
Conclusions:
- Troponin testing is a critical tool for risk stratification in suspected ACS.
- Tailoring treatment based on troponin status improves patient safety and outcomes.
- Differentiating troponin status is essential for effective management of chest pain presentations.
Abstract:
Providing the optimal treatment for patients who present to the emergency room with chest pains or suspected acute coronary syndrome (ACS) remains a dilemma for many practitioners due to subjectivity, delayed diagnoses, and widely variable mechanisms with similar clinical presentations. In treating patients with chest pain but no obvious electrocardiogram changes, practitioners frequently utilize the American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines. The guidelines group possible ACS patients together as unstable angina/non-ST-segment elevation myocardial infarction (NSTEMI) and recommend that treatment be based on level of risk. The challenge for practitioners is discriminating between "risk" and "treatable risk." Evaluation of troponin levels can help identify patients with possible ACS who are at high risk of death and MI, and guide early decision making. Available data indicate that in the troponin-negative patient, routine interventions such as unfractionated heparin, glycoprotein IIb/IIIa receptor antagonists, and invasive approaches have no benefit in terms of reducing death and MI. Although the ACC/AHA Guidelines combine patients with unstable angina and NSTEMI, it is essential to evaluate troponin status in order to optimize patient outcomes and safety in the treatment of suspected ACS.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Acute Coronary Syndrome V: Nursing Management
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures